KR20240154700A - 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 - Google Patents
이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 Download PDFInfo
- Publication number
- KR20240154700A KR20240154700A KR1020247034793A KR20247034793A KR20240154700A KR 20240154700 A KR20240154700 A KR 20240154700A KR 1020247034793 A KR1020247034793 A KR 1020247034793A KR 20247034793 A KR20247034793 A KR 20247034793A KR 20240154700 A KR20240154700 A KR 20240154700A
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- carboxylic acid
- pharmaceutically acceptable
- acceptable salt
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020257038778A KR20250167147A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628020P | 2018-02-08 | 2018-02-08 | |
| US62/628,020 | 2018-02-08 | ||
| US201862628541P | 2018-02-09 | 2018-02-09 | |
| US62/628,541 | 2018-02-09 | ||
| PCT/US2019/017201 WO2019157273A1 (en) | 2018-02-08 | 2019-02-08 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| KR1020207025754A KR20210007948A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207025754A Division KR20210007948A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257038778A Division KR20250167147A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240154700A true KR20240154700A (ko) | 2024-10-25 |
Family
ID=67475310
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247034793A Ceased KR20240154700A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| KR1020207025754A Ceased KR20210007948A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| KR1020257038778A Pending KR20250167147A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207025754A Ceased KR20210007948A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
| KR1020257038778A Pending KR20250167147A (ko) | 2018-02-08 | 2019-02-08 | 이명, 급성 감각신경성 난청, 메니에르병, 투렛 증후군, 주의력 결핍 과잉행동 장애 및 중독의 치료에 있어서 (1s,3s)-3-아미노-4-(디플루오로메틸리덴) 시클로펜탄-1-카르복시산 및 (s)-3-아미노-4-(디플루오로메틸리덴)시클로펜트-1-엔-1-카르복시산의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10653652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3735237A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021512920A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20240154700A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112261938A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019216742B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090258A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL276287B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020008359A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019157273A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389001B (es) | 2015-10-23 | 2025-03-20 | Navitor Pharm Inc | Moduladores de interacción de sestrina-gator2 y sus usos. |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| AU2019243586A1 (en) * | 2018-03-29 | 2020-10-15 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
| WO2020086816A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| AU2020376950B2 (en) | 2019-11-01 | 2026-06-11 | Supernus Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| US12678586B1 (en) | 2023-06-12 | 2026-07-14 | John Brundage | Noise injury relief system |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| JP2009517393A (ja) * | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
| CA2790820A1 (en) | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US20130230586A1 (en) * | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| ES2862673T3 (es) * | 2011-12-12 | 2021-10-07 | Zilentin AG | Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo |
| WO2013112363A1 (en) * | 2012-01-27 | 2013-08-01 | Catalyst Pharmaceutical Partners | Method of treating tourette's disorder with gaba-aminotransferase inactivators |
| CN108137484B (zh) * | 2015-10-09 | 2021-02-12 | 西北大学 | 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物 |
| KR20240110989A (ko) | 2017-02-08 | 2024-07-16 | 오비드 테라퓨틱스 인크. | 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들 |
-
2019
- 2019-02-08 US US16/270,856 patent/US10653652B2/en active Active
- 2019-02-08 KR KR1020247034793A patent/KR20240154700A/ko not_active Ceased
- 2019-02-08 KR KR1020207025754A patent/KR20210007948A/ko not_active Ceased
- 2019-02-08 AU AU2019216742A patent/AU2019216742B2/en active Active
- 2019-02-08 CN CN201980023215.6A patent/CN112261938A/zh active Pending
- 2019-02-08 KR KR1020257038778A patent/KR20250167147A/ko active Pending
- 2019-02-08 EP EP19750667.8A patent/EP3735237A4/en active Pending
- 2019-02-08 CA CA3090258A patent/CA3090258A1/en active Pending
- 2019-02-08 WO PCT/US2019/017201 patent/WO2019157273A1/en not_active Ceased
- 2019-02-08 MX MX2020008359A patent/MX2020008359A/es unknown
- 2019-02-08 JP JP2020542858A patent/JP2021512920A/ja active Pending
- 2019-02-08 IL IL276287A patent/IL276287B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020008359A (es) | 2020-11-24 |
| JP2021512920A (ja) | 2021-05-20 |
| KR20250167147A (ko) | 2025-11-28 |
| WO2019157273A1 (en) | 2019-08-15 |
| CN112261938A (zh) | 2021-01-22 |
| CA3090258A1 (en) | 2019-08-15 |
| US20190240174A1 (en) | 2019-08-08 |
| KR20210007948A (ko) | 2021-01-20 |
| EP3735237A4 (en) | 2021-03-17 |
| EP3735237A1 (en) | 2020-11-11 |
| AU2019216742A1 (en) | 2020-08-13 |
| IL276287B1 (en) | 2026-07-01 |
| IL276287A (en) | 2020-09-30 |
| AU2019216742B2 (en) | 2024-05-09 |
| US10653652B2 (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10653652B2 (en) | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction | |
| AU2002311784B8 (en) | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning | |
| EP3579826B1 (en) | Methods of treating cdkl5 disorders with the compound ov329 | |
| US20060252761A1 (en) | Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine | |
| JP2024178317A (ja) | 耳鳴りの処置におけるガボキサドールの使用 | |
| US12285397B2 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | |
| AU2002311784A1 (en) | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning | |
| JP2009517393A (ja) | 不安症の治療方法 | |
| US11771671B2 (en) | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction | |
| KR20210038843A (ko) | 주의력 결핍 과잉 행동 장애를 치료하는 방법 | |
| WO2005016319A2 (en) | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning | |
| JP2002521433A (ja) | モクロベマイドを用いる、ある種の精神医学的および医学的異常の処置と予防の方法および組成物 | |
| HK40015478A (en) | Use of gaboxadol in the treatment of tinnitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |